OXALIPLATIN Drug Patent Profile
✉ Email this page to a colleague
When do Oxaliplatin patents expire, and when can generic versions of Oxaliplatin launch?
Oxaliplatin is a drug marketed by Accord Hlthcare, Actavis, Actavis Totowa, Am Regent, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hengrui Pharma, Hospira Inc, Hospira Worldwide, Kindos, Mylan Labs Ltd, Novast Labs, Qilu Pharm Hainan, Sandoz, Sun Pharm, and Teva Pharms. and is included in twenty-seven NDAs.
The generic ingredient in OXALIPLATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxaliplatin
A generic version of OXALIPLATIN was approved as oxaliplatin by HOSPIRA WORLDWIDE on August 7th, 2009.
Summary for OXALIPLATIN
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 27 |
Finished Product Suppliers / Packagers: | 19 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Clinical Trials: | 2,038 |
Patent Applications: | 406 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for OXALIPLATIN |
What excipients (inactive ingredients) are in OXALIPLATIN? | OXALIPLATIN excipients list |
DailyMed Link: | OXALIPLATIN at DailyMed |
Recent Clinical Trials for OXALIPLATIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Institut Cancerologie de l'Ouest | Phase 3 |
Grünenthal GmbH | Phase 3 |
Mansoura University | Phase 1/Phase 2 |
Pharmacology for OXALIPLATIN
Drug Class | Platinum-based Drug |
Anatomical Therapeutic Chemical (ATC) Classes for OXALIPLATIN
Paragraph IV (Patent) Challenges for OXALIPLATIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ELOXATIN | Injection | oxaliplatin | 5 mg/mL, 40 mL vials | 021759 | 1 | 2007-07-16 |
ELOXATIN | Injection | oxaliplatin | 5 mg/mL, 10 mL and 20 mL vials | 021759 | 11 | 2007-02-09 |
US Patents and Regulatory Information for OXALIPLATIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novast Labs | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 207562-001 | Oct 16, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hospira Worldwide | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 078813-001 | Aug 7, 2009 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sandoz | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 078817-001 | Jan 24, 2011 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva Pharms | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 022160-002 | Aug 7, 2009 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Qilu Pharm Hainan | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 204368-002 | Jun 7, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sandoz | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 090849-001 | Apr 28, 2011 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sun Pharm | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 202922-001 | Apr 8, 2014 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |